January 1, 2012Thrombosis and Haemostasis
Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction
Why the study?
Does prior myocardial infarction or prior aspirin use affect platelet aggregation and thromboxane levels in patients with coronary artery disease on aspirin mono-therapy?
Population
231 patients with coronary artery disease on aspirin mono-therapy, including 171 with prior myocardial…
Comparison
Aspirin 75 mg mono-therapy vs Patients without prior MI; and among MI…
Design
Cross-sectional
Authors
Discussion
Loading...
Member takes
Implication
Prior MI was associated with higher on-aspirin platelet reactivity; hypothesis-generating for altered responsiveness, needs prospective confirmation.
Structured PICO
Does prior myocardial infarction or prior aspirin use affect platelet aggregation and thromboxane levels in patients with coronary artery disease on aspirin mono-therapy?
P
Population
231 patients with coronary artery disease on aspirin mono-therapy, including 171 with prior myocardial infarction (MI) and 60 without prior MI.
I
Intervention
Aspirin 75 mg mono-therapy
C
Comparator
Patients without prior MI; and among MI patients, those not on aspirin at the time of MI onset
O
Outcome
Platelet aggregation (assessed by Multiplate and VerifyNow), platelet activation (soluble P-selectin), and serum thromboxane B2 levelssurrogate
Patients with prior MI, especially those on aspirin before MI onset, exhibit higher platelet aggregation and thromboxane levels despite aspirin therapy, suggesting altered aspirin responsiveness.
Cite This Study
Larsen et al. (2012) studied this question.